Xenon Pharmaceuticals Cash Flow Statement
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
36.44+0.28 (+0.77%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xenon Pharmaceuticals free cash flow
In fiscal 2025, Xenon Pharmaceuticals generated -$279.1 million of operating cash flow and spent $799,000 on capital expenditures. That left free cash flow of -$279.9 million, a free-cash-flow margin of -3732.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Xenon Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -345.91M | -234.33M | -182.39M | -125.37M | -78.88M | -28.84M | -41.59M | -34.50M | -30.70M | -23.00M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.54M | 2.56M | 2.06M | 1.41M | 906.00K | 644.00K | 429.00K | 586.00K | 649.00K | 864.00K |
| Stock-Based Compensation | 53.71M | 50.72M | 32.37M | 20.38M | 10.02M | 5.68M | 2.92M | 2.63M | 2.24M | 2.16M |
| Change in Working Capital | 5.55M | 6.93M | 5.63M | -676.00K | -2.65M | -26.09M | 33.52M | 135.00K | 378.00K | 1.02M |
| Operating Cash Flow | -279.12M | -181.39M | -151.11M | -101.03M | -69.50M | -48.12M | -4.71M | -34.72M | -28.73M | -19.57M |
| Capital Expenditures | -799.00K | -3.08M | -5.62M | -2.89M | -2.05M | -2.64M | -1.24M | -507.00K | -315.00K | -279.00K |
| Investing Cash Flow | 218.00M | 165.00M | -111.39M | -293.40M | -246.77M | -16.82M | -66.21M | -28.99M | 24.29M | -47.84M |
| Debt Issued | — | — | — | — | — | — | — | 8.45M | 6.89M | — |
| Financing Cash Flow | 117.11M | 12.13M | 353.52M | 278.47M | 447.54M | 85.80M | 27.52M | 111.59M | 7.07M | 23.96M |
| Net Change in Cash | 56.45M | -5.93M | 91.40M | -118.45M | 130.68M | 20.25M | -43.00M | 47.27M | 3.39M | -41.56M |
| Free Cash Flow | -279.92M | -184.46M | -156.73M | -103.92M | -71.55M | -50.76M | -5.95M | -35.23M | -29.04M | -19.85M |
This table shows 10 annual periods of Xenon Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow XENE's reporting calendar. What is a cash flow statement?